But since Russia is so heavily experienced with FDA trials and reporting in English to CROs from those prior trials, I would expect they have pretty well worked all the bugaboos in the communication/database end of the reporting.

Not as though this is their first rodeo. That is why I believe CRO may be a bit further along in the data analysis than we have heard.

Sorry, hadn't read JFMs two prior posts. My thinking is along his line of thinking.